Evidence map›Paper›PMID 33184109›Full record

ArticleCancer research2021

Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects.

Spencer Arnesen, Zannel Blanchard, Michelle M Williams, Kristofer C Berrett, Zheqi Li, Steffi Oesterreich, Jennifer K Richer, Jason Gertz

Open access · bronzeAbstract readComment
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Spencer ArnesenDepartment of Oncological Sciences, University of Utah, Salt Lake City, Utah.ORCID https://orcid.org/0000-0002-4235-6684
Zannel BlanchardDepartment of Oncological Sciences, University of Utah, Salt Lake City, Utah.
Michelle M WilliamsDepartment of Pathology, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.
Kristofer C BerrettDepartment of Oncological Sciences, University of Utah, Salt Lake City, Utah.
Zheqi LiWomen's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee-Womens Research Institute, Pittsburgh, Pennsylvania.
Steffi OesterreichWomen's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee-Womens Research Institute, Pittsburgh, Pennsylvania.ORCID https://orcid.org/0000-0002-2537-6923
Jennifer K RicherDepartment of Pathology, Anschutz Medical Campus, University of Colorado, Aurora, Colorado.ORCID https://orcid.org/0000-0002-9960-0991
Jason GertzDepartment of Oncological Sciences, University of Utah, Salt Lake City, Utah. Jay.Gertz@hci.utah.edu.
University of Utah · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Pittsburgh · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Training Program in Cancer BiologyT32CA190216 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2016 to 2026
$3.5M
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancerR01CA221303 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI OESTERREICH, STEFFI · 2018 to 2022
$2.0M
Impact of heme catabolism on triple negative breast cancer metastasis via immune-suppressionF32CA239436 · NCI · UNIVERSITY OF COLORADO DENVER · PI WILLIAMS, MICHELLE M · 2020 to 2021
$142k
NCI NIH HHS F32 CA239436NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA221303NCI NIH HHS T32 CA190216
6 · The paper itself

Abstract

While breast cancer patients with tumors that express estrogen receptor α (ER) generally respond well to hormone therapies that block ER activity, a significant number of patients relapse. Approximately 30% of these recurrences harbor activating mutations in the ligand binding domain (LBD) of ER, which have been shown to confer ligand-independent function. However, much is still unclear regarding the effect of mutant ER beyond its estrogen independence. To investigate the molecular effects of mutant ER, we developed multiple isogenic ER-mutant cell lines for the most common LBD mutations, Y537S and D538G. These mutations induced differential expression of thousands of genes, the majority of which were mutant allele specific and were not observed upon estrogen treatment of wild-type (WT) cells. These mutant-specific genes showed consistent differential expression across ER-mutant lines developed in other laboratories. WT cells with long-term estrogen exposure only exhibited some of these transcriptional changes, suggesting that mutant ER causes novel regulatory effects that are not simply due to constant activity. While ER mutations exhibited minor effects on ER genomic binding, with the exception of ligand independence, ER mutations conferred substantial differences in chromatin accessibility. Mutant ER was bound to approximately a quarter of mutant-enriched accessible regions that were enriched for other DNA binding factors, including FOXA1, CTCF, and OCT1. Overall, our findings indicate that mutant ER causes several consistent effects on gene expression, both indirectly and through constant activity. SIGNIFICANCE: This study demonstrates the multiple roles of mutant ER in breast cancer progression, including constant ER activity and secondary regulatory effects on gene expression and chromatin accessibility. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/3/539/F1.large.jpg.

Indexed as

Breast NeoplasmsEstrogen Receptor alphaGene ExpressionHumansMutationNeoplasm Recurrence, LocalEstrogen Receptor alpha

Identifiers

PMID33184109
PMCPMC7854489
OpenAlexW3102914996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.